mfn-cus-mitokondrier – Page 2

28 May, 2020

NeuroVive Pharmaceutical changes its name to Abliva

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) announced today that the company’s application for a change of name to Abliva AB (publ) has been approved by the Swedish Companies Registration Offi ...

20 May, 2020

Regulatory

Interim Report January-March 2020

Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for […]

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...